Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study
- 2 May 2016
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 63 (8) , 1407-1413
Abstract
Background Data on second‐line treatment options for pediatric patients with immune thrombocytopenia (ITP) are limited. Thrombopoietin receptor agonists (TPO‐RA) provide a nonimmunosuppressive option for children who require an increased platelet count. Procedure We performed a multicenter retrospective study of pediatric ITP patients followed at ITP Consortium of North America (ICON) sites to characterize TPO‐RA use. Results Seventy‐nine children had a total of 87 treatments (28 eltrombopag, 43 romiplostim, and eight trialed on both). The majority had primary ITP (82%) and most (60.8%) had chronic ITP. However, 22% had persistent ITP and 18% had newly diagnosed ITP. During the first 3 months of treatment, 89% achieved a platelet count ≥ 50 × 109/l (86% romiplostim, 81% eltrombopag, P = 0.26) at least once in the absence of rescue therapy. The average time to a response was 6.4 weeks for romiplostim and 7.0 weeks for eltrombopag (P = 0.83). Only 40% of patients demonstrated a stable response with consistent dosing over time. An intermittent response with constant dose titration was seen in 15%, and an initial response that waned to no response was seen in 13%. Significant adverse events were minimal with the exception of two patients with thrombotic events and one who developed a neutralizing antibody. Conclusions Our results demonstrate that TPO‐RA agents are being used in children with ITP of varying duration and severity. The response was similar to clinical trials, but the sustainability of response varied. Future studies need to focus on the ideal timing and rationale for these medications in pediatric patients.Keywords
Funding Information
- Terrana Fund for ITP Research (Boston Children's Hospital)
- National Institutes of Health (K12 HL087164)
This publication has 36 references indexed in Scilit:
- Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension studyInternational Journal of Hematology, 2013
- Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND studyBlood, 2013
- Repeated short‐term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)British Journal of Haematology, 2012
- A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopeniaJournal of Thrombosis and Haemostasis, 2012
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 studyThe Lancet, 2011
- Romiplostim or Standard of Care in Patients with Immune ThrombocytopeniaNew England Journal of Medicine, 2010
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- Splenectomy and spontaneous remission in children with chronic idiopathic thrombocytopenic purpuraPediatric Blood & Cancer, 2006
- Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpuraBlood, 2006
- Splenectomy for Chronic Idiopathic Thrombocytopenic Purpura in Children: A Single Center Study in ChinaActa Haematologica, 2006